HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors

Vulvar squamous cell carcinomas (VSCC) represent the most common carcinoma of the female external genitalia, with increasing incidence. Although high-risk human papillomavirus (HPV) infection has long been implicated in the majority of cervical and anal squamous cell carcinomas, there is uncertainty about its prevalence and prognostic impact in VSCC. In this study, we conducted a retrospective integrated morphologic and multimodal HPV analysis of a cohort of 114 VSCC cases treated at the Princess Margaret Cancer Centre/University Health Network, Toronto, Canada between 2000 and 2010. VSCC histology was reviewed. We analyzed the cohort for HPV using polymerase chain reaction based method, and tissue microarray DNA and RNA in situ hybridization (ISH), and p16 immunohistochemistry. Among the 114 cases (age 70±16 yr), 36.7% of cases were classified as having histomorphology of HPV infection. HPV was detected in 31.9% (polymerase chain reaction), 14.0% (DNA ISH), and 27.3% (RNA ISH) of cases. p16 immunohistochemistry was positive in 37.8% of cases. On univariate analysis, HPV morphology (P=0.009), p16+ (P=0.00013), DNA ISH+ (P=0.021), and RNA ISH+ (P=0.00061) were associated with better 5-yr progression-free survival. DNA ISH+ (P=0.049) was associated with better 5-yr overall survival. On multivariate analysis, HPV morphology (P=0.033), p16+ (P=0.01), and RNA ISH+ (P=0.035) were associated with better 5-yr progression-free survival. In conclusion, a subset of VSCC is associated with HPV, which correlates with better outcome. Relatively inexpensive tests such as histomorphologic evaluation, p16 immunohistochemistry, and HPV RNA ISH can be used to predict outcome in VSCC. Therefore, routine reporting of HPV status in VSCC is recommended.

[1]  P. Catalano,et al.  Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. , 2016, Gynecologic oncology.

[2]  M. Tsao,et al.  Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients. , 2013, Lung cancer.

[3]  J. Ordi,et al.  Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma , 2013, Histopathology.

[4]  M. Henry,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations From the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology , 2012, Archives of pathology & laboratory medicine.

[5]  M. Goodman,et al.  Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction , 2012, Journal of lower genital tract disease.

[6]  J. Flanagan,et al.  High-Risk Human Papillomavirus E6/E7 mRNA Detection by a Novel In Situ Hybridization Assay Strongly Correlates With p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma , 2011, The American journal of surgical pathology.

[7]  J. Ordi,et al.  Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? , 2011, Gynecologic oncology.

[8]  M. Tsao,et al.  The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck , 2011, Head & neck oncology.

[9]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[10]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[11]  H. Jacobsson,et al.  Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. , 2010, Gynecologic oncology.

[12]  W. Melchers,et al.  The Etiologic Role of HPV in Vulvar Squamous Cell Carcinoma Fine Tuned , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  P. Judson,et al.  Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma , 2006, Obstetrics and gynecology.

[14]  R. Bollmann,et al.  HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN) , 2006, International Journal of Colorectal Disease.

[15]  M. Mukai,et al.  Comparison Between In Situ Hybridization and Real-time PCR Technique as a Means of Detecting the Integrated Form of Human Papillomavirus 16 in Cervical Neoplasia , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  K. Cooper,et al.  Biotinyl-Tyramide-Based In Situ Hybridization Signal Patterns Distinguish Human Papillomavirus Type and Grade of Cervical Intraepithelial Neoplasia , 2002, Modern Pathology.

[17]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[18]  B. Monk,et al.  Prognostic significance of human papillomavirus DNA in vulvar carcinoma , 1995 .

[19]  K. Metze,et al.  HPV in situ hybridization signal patterns as a marker for cervical intraepithelial neoplasia progression. , 2009, Gynecologic oncology.

[20]  W. R. Hart Vulvar intraepithelial neoplasia: historical aspects and current status. , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  A. Ferenczy,et al.  Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. , 1997, British Journal of Cancer.